← Eichor
Study identifier: NCT04934228 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Mitigating the Pro-inflammatory Phenotype of Obesity

Condition: Blood Pressure · Diabetes · Obesity  ·  Sponsor: University of Kansas Medical Center

PhasePhase 1
Planned participants60
Who can joinAll sexes, 18 Years to 79 Years
Healthy volunteersNo

About this study

The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Seth W Holwerda, Ph,D  ·  9729223230  ·  sholwerda@kumc.edu

Davina A Clonch  ·  9132266009  ·  dclonch@kumc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Kansas Medical CenterKansas City, Kansas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04934228